Rapt Therapeutics, Inc. Stock Price, News & Analysis

RAPT Therapeutics (Nasdaq: RAPT) said members of management will participate in three investor conferences in November 2025: Guggenheim's 2nd Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and TD Cowen Virtual Immunology & Inflammation Summit.

Each participation is a fireside chat on consecutive days: Nov 11, 2025 at 3:30 p.m. ET, Nov 12, 2025 at 2:40 p.m. ET, and Nov 13, 2025 at 2:30 p.m. ET. Live webcasts and archived recordings will be available at https://investors.rapt.com/events-and-presentations.

RAPT (Nasdaq: RAPT) initiated the randomized, double-blind, placebo-controlled prestIgE Phase 2b trial of ozureprubart (RPT904) in IgE-mediated food allergy on Oct 27, 2025. The study will run at approximately 30 sites across the U.S., Canada and Australia and tests two dosing regimens (subcutaneous every 8 weeks or every 12 weeks, with a loading dose) versus placebo in a 2:2:1 ratio.

Part 1 will treat ~100 participants with at least one food allergy (peanut, milk, egg, walnut or cashew) for 24 weeks with a primary endpoint measured by DBPCFC at Week 24. Part 2 continues treatment to Week 48 with a DBPCFC at Week 48 and a 16-week safety follow-up. The program follows prior promising Phase 2 data in chronic spontaneous urticaria and positions ozureprubart as a long‑acting anti‑IgE bio‑better targeting the same epitope as omalizumab.

RAPT Therapeutics (Nasdaq: RAPT) priced an underwritten public offering of 8,333,334 common shares at $30.00 per share, with expected gross proceeds of approximately $250.0 million before fees. The company granted underwriters a 30-day option to purchase up to an additional 1,250,000 shares at the public offering price, less discounts and commissions.

The offering is expected to close on or about October 23, 2025, subject to customary closing conditions, and is being conducted under a shelf registration declared effective by the SEC on August 17, 2023. Joint bookrunning managers and lead managers were named and a final prospectus supplement will be filed with the SEC.

RAPT Therapeutics (Nasdaq: RAPT) announced on October 21, 2025 that it has commenced an underwritten public offering of common stock. The company said it expects to grant underwriters a 30-day option to buy up to an additional 15% of the shares at the public offering price, less underwriting discounts and commissions.

The offering is subject to market conditions and may be completed only by means of a prospectus supplement filed with the SEC; all shares are being offered by RAPT.

RAPT (Nasdaq: RAPT) and Shanghai Jeyou announced positive topline Phase 2 results for RPT904 (JYB1904) in chronic spontaneous urticaria (CSU) on Oct 20, 2025. In a randomized, double-blind 137-patient study, RPT904 dosed every 8 weeks (Q8W) or 12 weeks (Q12W) produced numerically greater UAS7 reductions and higher proportions of patients with UAS7=0 at Weeks 8, 12 and 16 versus omalizumab dosed Q4W. RPT904 showed durability to Week 16 after a single dose and was well tolerated with no serious adverse events related to study drug. Jeyou will advance RPT904 to Phase 3 in China; RAPT will discuss a Phase 3 path with the FDA and host a conference call on Oct 20, 2025.

RAPT Therapeutics (Nasdaq: RAPT) announced it will report topline data from the Phase 2 trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria (CSU) on October 20, 2025.

The data were generated by partner Shanghai Jeyou Pharmaceutical. RAPT will host a webcast and conference call with slides on Monday, October 20, 2025 at 8:30 a.m. ET. Investors may pre-register for phone participation to join live Q&A and can access the live webcast and audio archive via RAPT's investor website at https://investors.rapt.com/events-and-presentations.

RAPT Therapeutics (Nasdaq: RAPT) has received FDA clearance for its Investigational New Drug (IND) Application to proceed with a Phase 2b clinical trial of RPT904 for food allergy treatment. The trial will be a randomized, double-blind, placebo-controlled study evaluating RPT904's safety and efficacy with dosing intervals of 8 and 12 weeks.

The company plans to initiate the trial by the end of 2025. RPT904 is RAPT's next-generation, half-life extended anti-IgE molecule. Additional data from RAPT's Chinese partner Jeyou's Phase 2 trials in chronic spontaneous urticaria and asthma is expected by year-end.

RAPT Therapeutics (NASDAQ: RAPT), a clinical-stage biopharmaceutical company specializing in immunology-based therapies, has announced its participation in four major investor conferences in September 2025.

The company will present at the Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), H.C. Wainwright Global Investment Conference (Sept 9), and Stifel Virtual Immunology & Inflammation Forum (Sept 15). All presentations will be accessible via webcast on the company's investor relations website.

RAPT Therapeutics (NASDAQ: RAPT) has reported its Q2 2025 financial results, marking a period of strategic developments and pipeline progress. The company posted a net loss of $17.6 million for Q2 2025, showing significant improvement from the $27.7 million loss in Q2 2024.

Key highlights include strengthening the leadership team with new appointments and advancing their clinical programs. Research and development expenses decreased to $12.3 million from $22.6 million year-over-year, while G&A expenses slightly increased to $7.2 million. The company maintains a strong financial position with $168.9 million in cash and marketable securities as of June 30, 2025.

RAPT remains on track to initiate a Phase 2b trial of RPT904 in food allergy and expects topline results from partner Jemincare's Phase 2 trials in CSU and asthma in H2 2025.